The Louisiana Board of Pharmacy (“Board”) sent a notice to manufacturers stating that the Louisiana Pharmacy Drug Cost Transparency Database website will no longer be accessible beginning July 1, 2023. Therefore, the Board stated that quarterly wholesale acquisition cost reports are no longer required to be submitted. In a follow-up communication, the Board stated that quarterly reports with the required information must still be submitted by pharmaceutical manufacturers and their marketers in an email to the Board.
Louisiana's Pharmaceutical Cost Transparency Law requires drug manufacturers or pharmaceutical marketers who engage in prescription drug marketing to a prescriber or to a prescriber's staff in Louisiana to provide the current WAC information for FDA-approved drugs marketed in the state to the Board of Pharmacy. Manufacturers previously registered for an account with the Louisiana Pharmaceutical Cost Transparency web portal.
For more information and updates, please visit Louisiana’s Price/Cost Disclosure section of the Transparency and Limitations Database on the PCD.